Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 20/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707233 | 1.00 | MCHR1 (1.00) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5258406 | 0.96 | MCHR1 (0.92) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5256418 | 0.95 | MCHR1 (0.91) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5259118 | 0.92 | MCHR1 (1.00) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5260769 | 0.92 | MCHR1 (1.00) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5256326 | 0.92 | MCHR1 (1.00) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5255718 | 0.90 | MCHR1 (0.82) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL13738209 | 0.89 | MCHR1 (0.80) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL5259428 | 0.89 | MCHR1 (0.80) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL14370191 | 0.89 | MCHR1 (0.80) | MCHR1CHRM4CYP3A4CHRM5ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | claimed |
| EP-4151210-A2 | PYRIDINE-CARBOLINE DERIVATIVES AS MCHR1 ANTAGONISTS FOR USE IN THERAPY | Harmony Biosciences, LLC (US) | 2023-03-22 | — | — | EP | claimed |
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | CONSYNANCE THERAPEUTICS INC (US) | 2023-03-16 | — | — | US | claimed |
| CN-115590966-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司（US） | 2023-01-13 | — | — | CN | claimed |
| US-20230002377-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | HARMONY BIOSCIENCES MANAGEMENT, INC. | 2023-01-05 | — | — | US | claimed |
| CN-115350184-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2022-11-18 | — | — | CN | claimed |
| EP-4076527-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | Consynance Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| CN-116322665-A | Methods and compositions for treating SARS-CoV-2 | 斯克里普斯研究学院 | 2023-06-23 | — | — | CN | disclosed |
| US-20230181673-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | DIAPIN THERAPEUTICS LLC | 2023-06-15 | — | — | US | disclosed |
| EP-4151210-A2 | PYRIDINE-CARBOLINE DERIVATIVES AS MCHR1 ANTAGONISTS FOR USE IN THERAPY | Harmony Biosciences, LLC (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | CONSYNANCE THERAPEUTICS INC (US) | 2023-03-16 | — | — | US | disclosed |
| WO-2007039177-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039171-A1 | 4-OXY-N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1442025-B1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-20040220404-A1 | Pyrimidinones as melanin concentrating hormone receptor 1 | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-11-04 | — | — | US | disclosed |
| EP-1442025-A1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003033476-A1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | MCHR1, MCHR2, MC1R | MCHR1 1/4885CHRM4 805/4885CYP3A4 728/4885 |
| US-20040220404-A1 | Pyrimidinones as melanin concentrating hormone receptor 1 | MC1R, MCHR1, MCHR2 | MCHR1 2/4885CHRM4 2712/4885CYP3A4 993/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | MCHR1 4105/4885CHRM4 1507/4885CYP3A4 752/4885 |
| US-20230002377-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | MCHR1, MCHR2, MC1R | MCHR1 1/4885CHRM4 1314/4885CYP3A4 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.